Last reviewed · How we verify

NCT07367581

Costotransverse Foramen Block Versus Thoracic Paravertebral Block in Thoracotomy for Lung Cancer

Recruiting now NA Last updated 27 January 2026
What this trial tests

NA trial testing Costotransverse foramen block in Costotransverse Foramen Block in 70 participants. Currently enrolling.

Timeline
24 January 2026
Primary endpoint
1 June 2026
1 June 2026

Quick facts

Lead sponsorNational Cancer Institute, Egypt
PhaseNA
StatusRecruiting now
Study typeINTERVENTIONAL
Allocationrandomized
Designparallel
Maskingdouble
Primary purposetreatment
Enrollment70
Start date24 January 2026
Primary completion1 June 2026
Estimated completion1 June 2026
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

National Cancer Institute, Egypt

Who can join

Adults 18 to 65, any sex, with Costotransverse Foramen Block or Thoracic Paravertebral Block. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This study aims to compare the costotransverse foramen block (CTFB) with thoracic paravertebral block (TPVB) in patients undergoing thoracotomy for lung cancer.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other trials of Costotransverse foramen block

Trials testing the same drug.

Other recruiting trials for Costotransverse Foramen Block

Currently open trials in the same condition.

Other National Cancer Institute, Egypt trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT07367581.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing